Efficacy of surgical microwave ablation for recurrent hepatocellular carcinoma after curative hepatectomy

Abstract

Background: Little evidence exists regarding postrecurrence survival after microwave ablation for recurrent hepatocellular carcinoma (HCC) after curative hepatectomy; we aimed to evaluate the feasibility of surgical microwave ablation.Methods: In this retrospective review, we enrolled patients who underwent curative hepatectomy for primary HCC in our department and had intrahepatic recurrence. We analyzed overall survival according to treatment modality to clarify the prognostic factors for survival.Results: Of 257 patients, 119 had intrahepatic recurrence. Three patients underwent repeat hepatectomy; 75 patients underwent surgical microwave ablation, and 34 patients underwent transcatheter arterial chemoembolization or hepatic arterial infusion chemotherapy. The median postrecurrence survival time and 5-year postrecurrence survival after surgical microwave ablation were 37.4 months and 55.4%, respectively. The major complication rate (Clavien-Dindo classification IIIa or above) after surgical microwave ablation was 5.3% with no mortality. Multivariate analysis showed that microvascular invasion at primary tumors, and recurrent tumors within 3 cm and 3 nodules were independent prognostic factors for overall survival after surgical microwave ablation for recurrent HCC. Conclusion:Our results suggested that surgical microwave ablation is safe and feasible for recurrent intrahepatic HCC after curative hepatectomy. Close follow-up and further curative treatment could be important for improving postrecurrence survival.

Feasibility and safety of surgical microwave ablation for hepatocellular carcinoma in elderly patients: a single center analysis in Japan

“…Renal disease, n (%) 2 (2) Respiratory disease, n (%) 1 (1) Dementia, n (%) 1 (1) Past history of malignant disease 16 (14) HBs-Ag, n (%) 7 www.nature.com/scientificreports/ OS of 43-60% [11][12][13][14]27 . We have performed surgical microwave ablation, termed microwave coagulo-necrotic therapy (MCN), as one of the treatment modalities of HCC patients for more than 20 years, and previously reported its feasibility, safety, and long-term outcomes [14][15][16][17] . In our recent propensity score matching analysis, we clarified that MCN provided almost equivalent OS and RFS as hepatic resection for single HCC of < 5 cm with less invasive perioperative outcomes 15 .…”

“…Several previous studies have also reported that microwave ablation showed comparative results compared to RFA for primary HCC when comparing local recurrence rates and long-term survival with 5-year OS of 43–60% 11 – 14 , 27 . We have performed surgical microwave ablation, termed microwave coagulo-necrotic therapy (MCN), as one of the treatment modalities of HCC patients for more than 20 years, and previously reported its feasibility, safety, and long-term outcomes 14 – 17 . In our recent propensity score matching analysis, we clarified that MCN provided almost equivalent OS and RFS as hepatic resection for single HCC of < 5 cm with less invasive perioperative outcomes 15 .…”

“…Several recent studies have reported that microwave ablation is an effective treatment for HCC [11][12][13][14] . We have performed surgical microwave ablation, termed microwave coagulo-necrotic therapy (MCN), not only for primary HCC but also for recurrent HCC since 1988, and reported its feasibility, safety and oncological long-term outcomes previously [14][15][16][17] . However, the feasibility and safety of microwave ablation in elderly HCC patients remains unknown.…”

A Fully Automated and Integrated Microfluidic System for Efficient CTC Detection and Its Application in Hepatocellular Carcinoma Screening and Prognosis

“…36 Thus, PLR combined with ablation or transarterial chemoembolization (TACE) may be a preferred program for some HCC patients with poor surgical tolerance or advanced tumor stage. 37,38 In this context, CTC may help to select candidates for PLR vs LT.…”

<p>Knockdown of FOXO6 Inhibits Glycolysis and Reduces Cell Resistance to Paclitaxel in HCC Cells via PI3K/Akt Signaling Pathway</p>

“…1,2 Due to the inconspicuous early symptoms, many HCC patients are only found to be in the advanced stage once diagnosed, depriving them of the opportunity for surgery and treatment. 3 Currently, hepatic artery perfusion chemotherapy is the mainstream treatment method for HCC; however, whose efficacy and prognosis turn out to be poor due to the emergence of resistance of HCC cells. 4 Therefore, exploring the mechanism of drug resistance of HCC cells is of great clinical significance for the treatment of HCC.…”